Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of generic febuxostat 80 mg versus FEBURIC 80 mg in healthy Thai volunteers
TCTR20260903013Phase 1Not yet recruiting
- Sponsor
- International Bio Service
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of febuxostat in hyperuricemia and gout (2 arms), sponsored by International Bio Service. Primary endpoints: Cmax, AUC0-tlast and 1 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
febuxostat
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on TCTR20260903013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260903013.